Combo Lipid-Lowering Drugs Will Help Drive Cholesterol Market In 2007 – IMS
Executive Summary
Patent losses this year for blockbuster lipid-lowering agents including Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will cause a six percentage point drop in growth in the class in 2007, but the advent of combination therapies are expected to help offset the negative impact, IMS Health projects
You may also be interested in...
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
J&J has slightly over one year to switch patients to Invega before its blockbuster atypical antipsychotic Risperdal loses patent protection
Bristol/Sanofi Push Plavix To Exhaust Generic Supply; Levels Remain Unclear
Bristol-Myers Squibb and Plavix marketing partner Sanofi-Aventis have ramped up promotional efforts for the blockbuster antithrombotic in an effort to exhaust outstanding generic supply as quickly as possible